title: Phase II trial of pirarubicin in epidermoid carcinoma of the head and neck.
authors.affiliation: Centre Oscar Lambret, Lille, France.
authors.forename: P
authors.initials: P
authors.lastname: Cappelaere
authors.forename: N
authors.initials: N
authors.lastname: Guiochet
authors.forename: J
authors.initials: J
authors.lastname: Chauvergne
authors.forename: P
authors.initials: P
authors.lastname: Bastit
authors.forename: J P
authors.initials: JP
authors.lastname: Armand
authors.forename: M A
authors.initials: MA
authors.lastname: Lentz
authors.forename: M
authors.initials: M
authors.lastname: Van Glabbeke
authors.forename: P
authors.initials: P
authors.lastname: Herait
authors.forename: P
authors.initials: P
authors.lastname: Fumoleau
mesh_terms: D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000556:secondary; D004317:Doxorubicin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged
chemical_list: D004317:Doxorubicin; C027260:pirarubicin